Early next year Vanda Pharmaceutical's schizophrenia drug Fanapt (generic: Iloperidone) will hit the pharmacy shelves. Could it be the first third-generation atypical? It blocks a different combination of neurotransmitters than earlier antipsychotics. The company says Fanapt targets a more relevant set of neurotransmitters, so that patients are... Read more
This is the second SharePost in a two-part series and will take a controversial stance. It is not so incendiary an idea as it is a novel idea-a surprising one that though unproven in the psychiatric field has recently held sway in the mainstream.
My take is that modest, consistent exercise and daily physical activity could improve the symptoms... Read more
This SharePost is the first of a two-part series and examines a greatly disabling symptom of schizophrenia: cognitive deficit. I quickly realized my near-photographic memory was not the norm. My psychiatrist told me, "Cognitive deficit is seen by leading schizophrenia researchers as the true hallmark of the illness." Unlike hearing voices whose... Read more
Today's Question of the Week was inspired by a creative writing exercise I discovered when I sat in on a workshop a woman led with young girls and teens. The prompt she gave was the introduction: "I Am From . . ." and you were supposed to write a poem starting with those words. This riffs on the responses to the last Question I posed... Read more
This SharePost will talk about Mental Illness Awareness Week [October 4 - 10]. The keyword in that sentence is awareness. What can be done, at our comfort level, to make people aware of what it's like to live with schizophrenia? Finding our voice often starts by revealing our stories to peers in a protective environment and then branching out... Read more